Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

The resolution of shortages for tirzepatide and other GLP-1 medications, such as semaglutide, signals a potential shift toward increased FDA enforcement as the agency works to align industry ...

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by ...

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

From 2020 to 2024, availability increased, especially in FFS; GLP-1 RA availability in MCOs plateaued at less than 60 percent since 2022. Tirzepatide was almost totally restricted.

Speakers at a congressional briefing on July 22 called on the FDA to take action against the marketing and distribution of ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

RELATED: Doctor Shares Her #1 Diet Tip to Lose That Stubborn Belly Fat After Menopause. For postmenopausal women struggling to lose weight, using tirzepatide (sold under ... these treatments more ...

When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the first glucagon-like peptide-1 (GLP-1) agonist to treat Type 2 diabetes.

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

Health How Making GLP-1s Available Over the Counter Can Unlock Their Full Potential Drugs like Ozempic might not only address obesity but also alcoholism, smoking, and drug addiction.